Clinical trials for Breast cancer

235 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05307705 #2022-000175-40
Phase 1B Partie E
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer #NCT05307705 #2022-000175-40
Phase 1B Partie B
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05307705 #2022-000175-40
Phase 1A
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer #NCT05307705 #2022-000175-40
Phase 1B Partie D
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer #NCT05307705 #2022-000175-40
Phase 1B Parties A, C et F
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer #NCT07015697
Partie 1 (Escalade de dose) et partie 2 (extension de dose) cancer du sein RH -, HER2 faible
Required HER2 statuses
HER2 Low
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
4 recruiting sites
Daiichi Sankyo
Phase 1 Breast cancer #NCT07015697
Partie 1 (Escalade de dose) et partie 2 (extension de dose) Cancer du sein HR+, HER2 faible
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
4 recruiting sites
Daiichi Sankyo
Phase 1 Breast cancer #NCT07015697
Partie 1 (Escalade de dose) et partie 2 (extension de dose) Cancer du sein HER2 +
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
4 recruiting sites
Daiichi Sankyo
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Lymphoma Ovarian / Fallopian tubes / Peritoneum cancer #NCT06514651 #2023-507774-41-00
Required disease stage
Metastatic
Required number of previous lines of therapy
1 2 3 or more
1 recruiting site
MabQuest SA
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT06253871 #2024-519188-17-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Iambic Therapeutics, Inc